Pricing

The UK has had in place what amount to two pricing schemes for branded medicines for years. But with major changes to both schemes set out in 2018, it’s now a new tale of two pricing schemes. Leela Barham reports.

The benefits and challenges of outcomes-based contracting.

Longitudinal databases can have several advantages for pharma companies in comparison to collecting data from clinical trials alone.

Among the new acronyms watch is UPI, or unjustified price increase, recently coined by ICER as part of its new workstream to explore price increases for both branded and generic drugs in the US.

How real-world evidence creates shared value for stakeholders across the healthcare spectrum.

An understanding of copay accumulator and maximizer benefit design programs.

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.

Bruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.

With copay accumulators, payers have drawn a line in the sand. How should pharma respond?

The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.

Charting the course that has led to payer vertical integration and what it may mean for pharma manufacturers.

Practitioners in the field of HEOR training and education outline how the best courses are responding to advancing industry needs.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

The biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.

Highlights of last year's ISPOR European Congress panel debated on one of the key issues regarding patient access to transformative treatments: adaptive pathways and the application of real-world evidence.

Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale

Outcomes-based contracting could be a potential game changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.

Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.

Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.

Payers and pharma must shift away from the traditional one drug–one price approach and expand "indication-based pricing", writes Anaïs Frappé.

If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

The significance of real-world data has been not utilized to the full potential, writes Uttam Barick.

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared-including the role of the patient in the equation.

To gain better alignment of coverage and risk, evidence-based arguments are critical during the underwriting process.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

Pharma leaders go on the defensive over drug pricing regulations, while experts slam the politicization of healthcare.